Harmony Biosciences Holdings (HRMY) Stock Analysis & Winston Score

Harmony Biosciences is a pharmaceutical company that focuses on treatments for rare and neurological sleep disorders. Its main product is Wakix (pitolisant), a prescription medication approved in the United States to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. Narcolepsy is a rare brain condition that makes it hard for people to stay awake, and Wakix is the only FDA-approved treatment that works through a specific brain chemical called histamine, making it unique among narcolepsy drugs. Harmony makes money by selling Wakix to patients through prescriptions written by neurologists and sleep specialists across the United States. The company operates almost entirely in the US market and generates strong gross margins above 76%, reflecting the pricing power that comes with having a differentiated drug in a small, specialized market. The key growth driver is expanding Wakix's use into additional patient populations and potentially new sleep-related conditions, while the main risk is competition from other narcolepsy treatments and the challenge of growing in a relatively small patient pool.